Cargando…
Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
Trastuzumab emtansine (T-DM1), an antibody-drug conjugate consisted of the HER2-targeted monoclonal antibody trastuzumab and the tubulin inhibitor emtansine, has shown potent therapeutic value in HER2-positive breast cancer (BC). However, a clinical trial indicated that T-DM1 exerts a limited effect...
Autores principales: | Zhang, Jinghui, Fan, Jiajun, Zeng, Xian, Nie, Mingming, Chen, Wei, Wang, Yichen, Luan, Jingyun, Zhu, Zeguo, Chang, Xusheng, Ju, Dianwen, Feng, Li, Yin, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969610/ https://www.ncbi.nlm.nih.gov/pubmed/33731670 http://dx.doi.org/10.1038/s41419-020-03349-1 |
Ejemplares similares
-
Correction: Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2023) -
Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment
por: Zhang, Jinghui, et al.
Publicado: (2021) -
The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
por: Liu, Peipei, et al.
Publicado: (2020) -
Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E
por: Wang, Yichen, et al.
Publicado: (2018) -
IL‐22‐mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury
por: Chen, Wei, et al.
Publicado: (2021)